CDKN2A and Miyoshi myopathy: Interestingly, our findings on MM were consistent with the data of Pezzuto et al., who found altered expression of p16 in patients with NSCLC, indicating that p16 could be a potential marker of lung cancer evolution and aggressiveness, unlike PD-L1 and Ki-67 which did not affect overall survival [47].